How Often Should You Get Blood Work Done? An Evidence-Based Guide
There is no single answer to how frequently you should have blood tests—it depends on your age, health conditions, medications, and personal risk factors. This guide synthesises current clinical guidelines to help you and your doctor set an appropriate testing schedule.
Why Testing Frequency Matters
Blood tests are a window into processes that have no outward symptoms until they are advanced. Dyslipidaemia, prediabetes, early kidney disease, and thyroid dysfunction can each silently progress for years before causing clinical disease. Catching these conditions early—when lifestyle or low-intensity treatment can reverse them—is the central rationale for periodic blood work.[1] But over-testing carries its own costs: false positives, unnecessary anxiety, and additional procedures. The goal is a testing schedule calibrated to your actual risk profile.
General Recommendations for Healthy Adults
Most major clinical guidelines converge on the following framework for adults with no known chronic conditions. These are starting points, not rigid rules—your clinician will adjust based on your individual picture.
Ages 18–39: A baseline comprehensive panel (CBC, CMP, lipid panel, fasting glucose, and thyroid) is reasonable in early adulthood. After that, the U.S. Preventive Services Task Force (USPSTF) recommends lipid screening every 5 years in low-risk individuals and blood pressure monitoring at every clinical encounter.[3] Fasting glucose or HbA1c every 3 years is appropriate if overweight or with other diabetes risk factors.[2]
Ages 40–49: Annual or biennial comprehensive panels become more valuable as metabolic risk rises. Fasting glucose and HbA1c should be checked at least every 3 years in the absence of risk factors, and more frequently if borderline results have been noted. The American Heart Association endorses lipid panel reassessment every 4–6 years in healthy adults, though annual checks are reasonable if values have been borderline.[3]
Ages 50 and above: Annual blood work is widely recommended. Panels typically include CBC, CMP, lipid panel, HbA1c, TSH, and vitamin D. After 65, kidney function (creatinine and eGFR) and complete metabolic markers warrant close attention given the rising prevalence of chronic kidney disease and medication-related electrolyte disturbances.[4]
Conditions That Require More Frequent Testing
Several chronic conditions fundamentally change the calculus of how often to test.
Type 2 diabetes: HbA1c every 3 months when glycaemic targets are not met, or every 6 months when stable.[2] Kidney function (eGFR, urine albumin-to-creatinine ratio) annually, with more frequent checks if eGFR is declining. Lipid panel annually.
Hypothyroidism: TSH every 6–12 months after a stable dose of levothyroxine is established. More frequent testing (every 6–8 weeks) when the dose is being titrated or after any medication change.
Chronic kidney disease (CKD): Frequency scales with stage.[4] Stage 3 CKD typically warrants CMP and CBC every 6–12 months; stage 4 every 3–6 months; stage 5 monthly or as directed by nephrology.
Lipid disorders on statin therapy: A fasting lipid panel 4–12 weeks after initiating or adjusting therapy, then every 3–12 months depending on adherence and target attainment.[3] Liver enzymes (ALT) at baseline and if symptoms arise.
Autoimmune conditions: Varies considerably by disease and treatment. Patients taking methotrexate or other disease-modifying antirheumatic drugs (DMARDs) typically require CBC and liver function tests every 2–3 months.
Medications That Mandate Monitoring
Certain medications require periodic blood work not for disease monitoring but for drug safety. Anticoagulants such as warfarin require INR checks as often as weekly when initiating therapy, stabilising to monthly once in range. Lithium and valproate require serum levels and renal or liver function tests every 3–6 months. Long-term use of proton pump inhibitors may warrant annual magnesium and B12 assessment. NSAIDs used chronically justify periodic kidney function checks.
The Value of Tracking Trends
Individual blood test snapshots have limited predictive power compared to longitudinal trends. A single fasting glucose of 98 mg/dL tells you the number is normal. But if the same person's glucose was 82 mg/dL three years ago and 90 mg/dL two years ago, the upward trajectory is clinically meaningful even though no value has crossed a diagnostic threshold.
This is the central argument for consistent, structured blood work over time. Tools like the Health3 blood test frequency planner can help you build a personalised testing calendar based on your age, conditions, and medications, and track results across visits to surface trends your portal may not highlight.
When to Test Outside a Schedule
Scheduled preventive testing is not the only reason to order blood work. New symptoms—unexplained fatigue, significant weight change, persistent gastrointestinal symptoms, or changes in urination—are indications for targeted testing regardless of when you last had routine panels. Starting or changing a medication, becoming pregnant, or receiving a new diagnosis each warrant an updated baseline.
Key Takeaway: For healthy adults, annual comprehensive blood work from age 50 and targeted panels every 2–5 years in younger adults represents a reasonable baseline. Chronic conditions, medications, and new symptoms all accelerate that schedule. Consistent testing over time transforms snapshots into trends—and trends are where the clinical value lies.
Frequently Asked Questions
Track Your Biomarkers With Health3
Scan your lab results, explore biomarker interactions, and track trends over time with the Health3 app.
References
- Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease. Cochrane Database Syst Rev. 2019;1(1):CD009009. PubMed
- Siu AL; U.S. Preventive Services Task Force. Screening for abnormal blood glucose and type 2 diabetes mellitus. Ann Intern Med. 2015;163(11):861-868. PubMed
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082-e1143. PubMed
- Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63(5):713-735. PubMed
Medical Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making changes to your health regimen. Read our full Content Standards & Medical Disclaimer.